Inactive Instrument

Highlights Innovate Biopharmaceuticals Inc Nasdaq

Equities

US61174L5012

Highlights

Unlock all the news: Be the first to know and act before the market!

North American Morning Briefing : Tech in Focus on -2-	03-25	DJ
North American Morning Briefing : Investors Await Powell's Jackson Hole Speech	23-08-25	DJ
Illumina cuts annual profit forecast as biotech funding woes linger	23-08-09	RE
Illumina cuts annual profit forecast	23-08-09	RE
9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome	23-05-30	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
9 Meters Biopharma, Inc. Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity	23-04-05	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome	22-11-29	CI
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy	22-11-14	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
9 Meters Biopharma Launching 1-for-20 Reverse Stock Split; Shares Drop	22-10-17	MT
9 Meters Biopharma Reports Positive Final Results in Short Bowel Syndrome Trial; Shares Jumps After Hours	22-09-26	MT
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome	22-09-26	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome	22-06-30	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
North American Morning Briefing : Tech Futures -2-	22-05-13	DJ
9 Meters Biopharma, Inc. Enters into an Exclusive License Agreement with EBRIS Srl	22-04-13	CI
9 Meters Biopharma Says Patent Application Allowed for NM-136 to Treat Certain Metabolic Disorders	22-04-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Innovate Biopharmaceuticals Inc Nasdaq

Equities

US61174L5012

Highlights

Filters